In 2025, ESG professionals in life sciences face more complexity and more pressure than ever before. Political headwinds in the U.S., reporting rollbacks in Europe, and increasing scrutiny from stakeholders have made ESG initiatives an increasingly polarized area of the business. However, amid shifting priorities and blurred regulatory boundaries, one thing remains constant: the undeniable value of ESG as a driver of innovation, resilience, and positive impact across business, people, patients, and the planet.